BECONASE
LOE ApproachingNDANASALAEROSOL, METERED
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BECONASE by GSK is clinical pharmacology mechanism of action following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. Approved for recurrence of nasal polyps following surgical removal. First approved in 1981.
Drug data last refreshed 33m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BECONASE is a metered-dose nasal aerosol formulation of beclomethasone dipropionate, a topical corticosteroid approved to prevent recurrence of nasal polyps following surgical removal. It works through anti-inflammatory and vasoconstrictor effects, with the active metabolite beclomethasone-17-monopropionate (B-17-MP) providing high topical anti-inflammatory activity via glucocorticoid receptor modulation.
LOE Approaching
Product is approaching loss of exclusivity with limited recent commercial investment, suggesting a contracting team focused on managed decline rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. The mechanisms responsible for the anti-inflammatory action of beclomethasone dipropionate are unknown. Corticosteroids have been shown to…
Worked on BECONASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.